Wael Alghamdi

Dr. Wael Alghamdi

King Khalid University, Abhā, ‘Asīr, Saudi Arabia
orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2018 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
WAWael Alghamdi
Wael Alghamdi
MAMohammad H. Alshaer
Mohammad H. Alshaer
CPCharles A Peloquin
Charles A Peloquin
The 4-drug regimen of rifampin, isoniazid, pyrazinamide, and ethambutol is an inexpensive, reliable option for treating patients with drug-susceptible tuberculosis (TB). Its efficacy could be further improved by determining the free drug concentrations in plasma, knowing that only the unbound drug can freely penetrate to the tissues. Using an ultrafiltration technique, we determined the protein binding (PB) extent and variability of the first-line anti-TB drugs when given simultaneously to TB patients, representing a real-life case scenario. We used clinical samples routinely received by our laboratory. Plasma proteins were also measured. A protein-free medium was used to determine the nonspecific binding. Plasma samples from 22 patients were included, of which plasma proteins were measured for 18 patients. The median PB was determined for rifampin (88%; range, 72 to 91%), isoniazid (14%; range, 0 to 34%), pyrazinamide (1%; range, 0 to 7%), and ethambutol (12%; range, 4 to 24%). Plasma proteins were not found to be significant predictors for the PB of first-line anti-TB drugs. Rifampin PB was positively correlated with its plasma concentration ( P value = 0.0051). Conversely, isoniazid PB was negatively correlated with its plasma concentration ( P value = 0.0417). Age was found to have a significant effect on isoniazid PB ( P value = 0.0376). No correlations were observed in pyrazinamide or ethambutol. In conclusion, we have determined variable PB of rifampin, isoniazid, pyrazinamide, and ethambutol in patient plasma samples, with median values of 88, 14, 1, and 12%, respectively. In this small study, PB of rifampin and that of isoniazid are dependent on their plasma concentrations.

17 July 2017 in Expert Review of Clinical Pharmacology
Verified
Journal Article
Closed access
OAOmamah Alfarisi
Omamah Alfarisi
WAWael Alghamdi
Wael Alghamdi
MAMohammad H. Alshaer
Mohammad H. Alshaer
KDKelly E Dooley
Kelly E Dooley
CPCharles A. Peloquin
Charles A. Peloquin
Introduction: One-third of the world’s population is infected with Mycobacterium tuberculosis (M.tb.). Latent tuberculosis infection (LTBI) can progress to tuberculosis disease, the leading cause of death by infection. Rifamycin antibiotics, like rifampin and rifapentine, have unique sterilizing activity against M.tb. What are the advantages of each for LTBI or tuberculosis treatment? Areas covered: We review studies assessing the pharmacokinetics (PK), pharmacodynamics (PD), drug interaction risk, safety, and efficacy of rifampin and rifapentine and provide basis for comparing them. Expert commentary: Rifampin has shorter half-life, higher MIC against M.tb, lower protein binding, and better distribution into cavitary contents than rifapentine. Drug interactions for the two drugs maybe similar in magnitude. For LTBI, rifapentine is effective as convenient, once-weekly, 12-week course of treatment. Rifampin is also effective for LTBI, but must be given daily for four months, therefore, drug interactions are more problematic. For drug-sensitive tuberculosis disease, rifampin remains the standard of care. Safety profile of rifampin is better-described; adverse events differ somewhat for the two drugs. The registered once-weekly rifapentine regimen is inadequate, but higher doses of either drugs may shorten the treatment duration required for effective management of TB. Results of clinical trials evaluating high-dose rifamycin regimens are eagerly awaited.

28 May 2018 in Journal of Internal Medicine
Verified
Journal Article
Closed access
PDF file
CLChristoph Lange
Christoph Lange
WAWael Alghamdi
Wael Alghamdi
MAMohammad H. Alshaer
Mohammad H. Alshaer
Susanna BrighentiSusanna Brighenti
Susanna Brighenti
ADAndreas H. Diacon
Andreas H. Diacon
TSThomas Schön
Thomas Schön

21 September 2020 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
PDF file
WAWael Alghamdi
Wael Alghamdi
MAMohammad H. Alshaer
Mohammad H. Alshaer
GAGuohua An
Guohua An
AAAbdullah Alsultan
Abdullah Alsultan
MKMaia Kipiani
Maia Kipiani
CPCharles A Peloquin
Charles A Peloquin
The prolonged treatment duration for multidrug-resistant tuberculosis (MDR-TB) makes linezolid dosing difficult because of adverse effects associated with long-term use. We sought to find the optimal dosing regimen for linezolid across different MIC values. Pharmacokinetic (PK) data from TB patients were included from Brazil, Georgia, and two U.S. sites. Population PK modeling and simulation were performed. We used an f AUC (area under the unbound drug concentration-time curve)/MIC ratio of >119 as the PK/pharmacodynamic (PD) target and minimum (trough) concentrations of drug ( C min s) of 2 and 7 mg/liter as thresholds for toxicity.

1 May 2019 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
WAWael Alghamdi
Wael Alghamdi
AAAbdullah Alsultan
Abdullah Alsultan
MAMohammad H. Alshaer
Mohammad H. Alshaer
GAGuohua An
Guohua An
SAShahriar Ahmed
Shahriar Ahmed
CPCharles A Peloquin
Charles A Peloquin
Limited pharmacokinetic/pharmacodynamic (PK/PD) data exist on cycloserine in tuberculosis (TB) patients. We pooled several studies into a large PK data set to estimate the population PK parameters for cycloserine in TB patients.

1 July 2019 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
MAMohammad H. Alshaer
Mohammad H. Alshaer
WAWael Alghamdi
Wael Alghamdi
AAAbdullah Alsultan
Abdullah Alsultan
GAGuohua An
Guohua An
SAShahriar Ahmed
Shahriar Ahmed
CPCharles A Peloquin
Charles A Peloquin
Fluoroquinolones are group A drugs in tuberculosis guidelines. We aim to compare the culture conversion between new-generation (levofloxacin and moxifloxacin) and old-generation (ciprofloxacin and ofloxacin) fluoroquinolones, develop pharmacokinetic models, and calculate target attainment for levofloxacin and moxifloxacin. We included three U.S. tuberculosis centers. Patients admitted between 1984 and 2015, infected with drug-resistant tuberculosis, and who had received fluoroquinolones for ≥28 days were included. Demographics, sputum cultures and susceptibility, treatment regimens, and serum concentrations were collected. A time-to-event analysis was conducted, and Cox proportional hazards model was used to compare the time to culture conversion. Using additional data from ongoing studies, pharmacokinetic modelling and Monte Carlo simulations were performed to assess target attainment for different doses. Overall, 124 patients received fluoroquinolones. The median age was 40 years, and the median weight was 60 kg. Fifty-six patients (45%) received old-generation fluoroquinolones. New-generation fluoroquinolones showed a faster time to culture conversion (median 16 versus 40 weeks, P = 0.012). After adjusting for isoniazid and clofazimine treatment, patients treated with new-generation fluoroquinolones were more likely to have culture conversion (adjusted hazards ratio, 2.16 [95% confidence interval, 1.28 to 3.64]). We included 178 patients in the pharmacokinetic models. Levofloxacin and moxifloxacin were best described by a one-compartment model with first-order absorption and elimination. At least 1,500 to 1,750 mg levofloxacin and 800 mg moxifloxacin may be needed for maximum kill at the current epidemiologic cutoff values. In summary, new-generation fluoroquinolones showed faster time to culture conversion compared to the old generation. For optimal target attainment at the current MIC values, higher doses of levofloxacin and moxifloxacin may be needed.